COIOSDeep risk insights through multi-disciplinary research across the globe
red and black boat on water
Item new Peer-reviewed Added

MASLD fibrosis screening with sequential ELF testing and health equity in US veterans

An ELF blood test after an indeterminate FIB-4 score cost screened veterans health but gave the largest net population gain.

This distributional cost-effectiveness analysis compared six MASLD fibrosis screening strategies in 15 veteran subgroups defined by race/ethnicity and social vulnerability. One strategy added an Enhanced Liver Fibrosis (ELF) blood test for indeterminate FIB-4 scores, referring those scoring above 9.80. Against standard FIB-4 screening, it cut referrals and treatment, costing screened veterans 91,370 QALYs. Counting its savings as health elsewhere at $100,000 per QALY gave the largest net gain, 185,010 QALYs. It also gave the largest fall in health inequality on the Atkinson index (0.112%). Results depended on how much of the savings was assumed to become health for other patients.

Why it is interesting: ELF screening at a lower 9.00 cutoff gave screened veterans the largest direct gains. It was not preferred once health forgone elsewhere and distributional effects were counted.

Source
PharmacoEconomics, 20 November 2026
Paper
Distributional Cost-Effectiveness Analysis of Blood-Based Noninvasive Screening for MASLD among US Veterans: Assessing Health Equity Impact in the Era of Emerging Therapies
Authors
Chen W, Chang ST, Cheung RC, Chalfin DB, Sangha K, Kao SZ et al.
DOI
10.1007/s40273-026-01677-2
Type
Peer-reviewed article
Design
Distributional cost-effectiveness analysis (model-based, adapted published model), VHA perspective, 15 subgroups by race/ethnicity and Social Vulnerability Index quintile, $100,000/QALY opportunity-cost threshold, 2026 US dollars
Verdict
New finding
Driver
Value in health

Other drivers in Data, models and systems